Merit Medical Systems, Inc. (MMSI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Merit Medical Systems, Inc. (MMSI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Merit Medical to Participate in the Bank of America Healthcare Conference

SOUTH JORDAN, Utah, May 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that Merit management will participate in the Bank of America 2026 Health Care Conference, to be held in Las Vegas, Nevada, May 12-14, 2026.

GlobeNewsWire • May 8, 2026

Why Merit Medical (MMSI) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • May 5, 2026

Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)

Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026.

Seeking Alpha • May 2, 2026

Merit Medical Systems, Inc. (MMSI) Q1 2026 Earnings Call Transcript

Merit Medical Systems, Inc. (MMSI) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 1, 2026

Merit Medical Q1 Earnings & Revenues Beat Estimates, Sales View Up

MMSI tops Q1 estimates with 9% EPS growth and 7% revenue rise, while lifting its 2026 sales outlook amid steady segment and geographic gains.

Zacks Investment Research • May 1, 2026

Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance

Financial Highlights† Reported revenue of $381.9 million, up 7% Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* increased 4%, excluding revenue from divested product line GAAP operating margin of 11.6%, compared to 11.5% in prior year period Non-GAAP operating margin* of 19.7%, compared to 19.3% in prior year period GAAP EPS $0.68, up 39% Non-GAAP EPS* $0.94, up 9% Free cash flow* generation of $24.7 million, up 26% Business Developments On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25.5 million was paid in cash at closing On April 1, 2026, Merit acquired View Point Medical, Inc., manufacturer of the OneMark® Detection Imaging System and OneMark Tissue Markers, for $140 million, of which $90 million was paid in cash at closing Beginning in the first quarter of 2026, Merit reorganized the presentation of revenue into two product categories – Foundational and Therapeutic - to better reflect the clinical uses of our diverse portfolio of products** † Comparisons above are calculated for the current quarter compared with the first quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.

GlobeNewsWire • Apr 30, 2026

Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates

Merit Medical (MMSI) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.86 per share a year ago.

Zacks Investment Research • Apr 30, 2026

Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now

MMSI rides strong cardiovascular demand, therapeutic growth and innovation push, but tariffs, China pressure and OEM weakness cloud its near-term outlook.

Zacks Investment Research • Apr 15, 2026

Here's Why Merit Medical (MMSI) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Apr 8, 2026